Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
Summary: Bausch + Lomb (NYSE/TSX: BLCO) has revealed the presentation of 21 scientific posters at the Association for Research in Vision and Ophthalmology Annual Meeting. The posters showcase evaluations of consumer, pharmaceutical, surgical, and vision care products, as well as pipeline programs. Notably, a new dry eye nutritional supplement, Blink™ NutriTears®, stands out among the offerings. The company's commitment to advancing eye care through research and innovation is evident in this comprehensive display of data.
Positive: Bausch + Lomb is actively engaged in research and development, with a strong focus on scientific advancements in eye care products. The presentation of 21 scientific posters at a prestigious conference demonstrates the company's commitment to innovation and its broad portfolio of eye health solutions.
Negative: The company may face challenges in ensuring the successful development and commercialization of its pipeline programs and new products, including the dry eye nutritional supplement. The competitive landscape in the eye care industry could pose obstacles to market penetration and acceptance of these innovations.
21 Poster Presentations include Evaluations of Consumer, Pharmaceutical, Surgical and Vision Care Products and Pipeline Programs, Including a Novel Dry Eye Nutritional Supplement
The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company’s broad eye care portfolio, as well as pipeline innovations. These include a novel daily nutritional supplement formulated to address dry eye symptoms, which is the focus of two posters as well as a paper published recently in Frontiers in Ophthalmology.
“We’re focused on supporting research that advances scientific knowledge of our products and fosters the development of new innovations to serve the holistic needs of eye care professionals and consumers,” said Yehia Hashad, MD, executive vice president, Research & Development and chief medical officer, Bausch + Lomb. “The breadth of data being presented at this meeting, as well as the recent publication evaluating our novel nutritional supplement for dry eyes, Blink™ NutriTears®, underscore this ongoing commitment.”
Following is a complete list of titles and lead authors for each of these posters:
- “Analysis of Glare and its Impact on Retinal Image Quality in Intraocular lenses.” Hosten et al.
- “A Natural Language Processing Approach to Identify Patients with Uveitic Macular Edema in the IRIS® Registry.” Jin et al.
- “Clinical Evaluation of a Multi-Ingredient Oral Supplement on Dry Eye Symptoms and Tear Volume.” Barbour et al.
- “Clinical Evaluation of a Novel Lipid-Containing Eye Drop.” Yassine et al.
-
“Comparison of Clinical Studies from the US and
India of a Multi-Ingredient Oral Supplement.” Ryan et al. - “Comparison of a Novel Lipid Nano-Emulsion Eye Drop with an Existing Lubricating Eye Drop.” Morrow et al.
- “Development of an In Vitro Assay to Evaluate the Antioxidant Effects of Erythritol and Glycerin in Human Corneal Epithelial Cells.” VanDerMeid et al.
- “Effects of Perfluorohexyloctane on the Ocular Pharmacokinetics of Latanoprost and Prednisolone Acetate After Topical Administration to Rabbits.” Cavet et al.
- “Effects of Perfluorohexyloctane on Corneal Healing in an Ex Vivo Study of Rabbit Corneas.” Alexander et al.
- “Efficacy of Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Stratified by Baseline Severity.” Sheppard et al.
- “Enhancing Silicone Oil Removal Efficiency: A Comparative Study of Ultrasonic Vitrectomy Handpieces and Conventional Methods.” Higgins et al.
- “Evaluating a Novel Contact Solution Among Hydrogen Peroxide Lens Care Users.” Shahidi et al.
- “Evaluation of the Efficacy of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” DiVito et al.
- “Evaluation of Intermediate-Range of Focus with New Monofocal Plus IOLs.” Lau et al.
- “Evaluation of the Safety of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Vollmer et al.
- “Impact of Pupil Size on Vision Performance of a New Multifocal Daily Disposable Contact Lens.” Reindel et al.
- “In-Home Use Test of a Novel Contact Lens Solution in Contact Lens Wearers on the Verge of Dropout.” Rah et al.
- “Intraocular Pressure Optimized Performance Settings with Posterior Adaptive Fluidics (PAF), and 25 Gauge 25,000 cpm Dual-Action Vitrectomy Cutters.” Papour et al.
- “Phaco Longitudinal Mode Heat Generation, a Two-System Efficiency Comparison Study.” Dickerhoff et al.
- “Preclinical Toxicity Profile of Perfluorohexyloctane Ophthalmic Solution.” Vittitow et al.
- “Predictive Modeling of Clinical Performance of Novel Trifocal IOL.” Venkateswaran et al.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the
© 2024 Bausch + Lomb.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429786639/en/
Media Contacts:
Kristy Marks
kristy.marks@bausch.com
(908) 927-0683
Caryn Marshall
caryn.marshall@bausch.com
(908) 493-1381
Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735
Source: Bausch + Lomb Corporation
FAQ
What was announced by Bausch + Lomb at the Association for Research in Vision and Ophthalmology Annual Meeting?
When will the Association for Research in Vision and Ophthalmology Annual Meeting take place?
What is the focus of the two posters and a recent paper published by Bausch + Lomb?
Who is the executive vice president, Research & Development, and chief medical officer of Bausch + Lomb?
